Director, Hematology Oncology Division
Charles Westfield Coker Chair in GI Oncology, SC SmartState Center of Excellence
Dr. Britten, a noted expert in cancer drug development and Phase I Clinical Trials, is Director of the Division of Hematology Oncology and is Associate Director for Clinical Investigations at the MUSC Hollings Cancer Center.
Dr. Britten was recruited to MUSC in 2012 from UCLA’s Jonsson Comprehensive Cancer Center, where her leadership positions included serving as director of Protocol-Specific Research Support and associate director of the Signal Transduction and Therapeutics Program. Since joining MUSC, Dr. Britten has effectively led and expanded the Hollings Cancer Center Phase 1 Clinical Trials Program, developing not only her own program, but also mentoring a number of junior faculty and fellows.
Originally from Canada, Dr. Britten received her MD degree from the University of Toronto, and completed internship, residency and chief residency at the University of Western Ontario. She subsequently trained in medical oncology at the University of British Columbia in Vancouver, and completed a research fellowship in cancer drug development at the University of Texas at San Antonio. She joined the faculty at the University of California, Los Angeles, where she developed their solid tumor Phase I clinical trials program.
Dr. Britten has extensive experience in the medical oncology field at a national level, having served on multiple committees for the American Society of Clinical Oncology and is highly active in collaborative oncology networks. She was recently named one of the Principal Investigators for Hollings Cancer Center on the NCI Community Oncology Research Program (NCORP) grant to conduct multi-site cancer clinical trials and cancer care delivery research studies. She is currently Principal Investigator for more than a dozen Phase I clinical trials.
More on Dr. Britten
Carolyn D. Britten, M.D.
Dr. Britten's Research Interests
- Developmental Cancer Therapeutics